Showing 3091-3100 of 4063 results for "".
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin
- Nanoscope Announces 3-Year Vision Improvements from REMAIN Study of MCO-010 in RPhttps://modernod.com/news/nanoscope-announces-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2484207/Nanoscope Therapeutics announced 3-year follow-up data from the REMAIN study, the long-term extension of its pivotal phase 2b/3 RESTORE trial evaluating MCO-010, the company’s proprietary optogenetic therapy for retinitis pigmentosa (RP).
- First Lucentis Biosimilar Available in Pre-Filled Syringe Launched in Europehttps://modernod.com/news/first-lucentis-biosimilar-available-in-pre-filled-syringe-launched-in-europe/2484201/Formycon, Bioeq AG, and Teva Pharmaceutical announced the European launch of FYB201/Ranivisio, the first Lucentis biosimilar available in an EMA-approved pre-filled syringe (PFS) presentation. The rollout began in France in October 2025, with additio
- EyeCare Partners to Present New Research and Expertise at AAOhttps://modernod.com/news/eyecare-partners-to-present-new-research-at-aao/2484188/EyeCare Partners (ECP) announced its participation in the American Academy of Ophthalmology (AAO) 2025 annual meeting in Orlando. Physicians from EyeCare Partners will participate in a variety of presentations, panel discussions, and poster sessions, high
- Oculus Smartfield Perimeter Launches Aboard the International Space Station to Support Vision Researchhttps://modernod.com/news/oculus-smartfield-perimeter-launches-aboard-the-international-space-station-to-support-vision-research/2484168/Oculus announced that its Smartfield perimeter has successfully launched aboard the International Space Station (ISS) to support research on Spaceflight Associated Neuro-ocular Syndrome (SANS)—a condition known to affect astronauts’ vision during l
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement
- Generational Differences Drive Contact Lens Choices and Technology Appeal, New Research Findshttps://modernod.com/news/generational-differences-drive-contact-lens-choices-and-technology-appeal-new-research-finds/2484156/The motivations for wearing contact lenses and the appeal of new lens technologies vary significantly by generation, according to new research from the Contact Lens Institute (CLI) to be presented this week at the 2025 American Academy of Optometry annual meet
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th